MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$2,254,173
EPS
-$0.53
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
1,071,536
341,468
403,654.5*
429,691
General and administrative
1,235,692
1,374,522
1,240,752.5*
1,599,010
Total operating expenses
2,307,228
1,715,990
1,644,407
2,028,701
Operating loss
-2,307,228
-1,715,990
-1,644,407*
-2,028,701
Interest income
53,055
35,008
36,472.5*
35,911
Net loss
-2,254,173
-1,680,982
-1,607,934.5
-1,992,790
Basic EPS
-0.53
-0.62
-0.957
-1.23
Diluted EPS
-0.53
-0.62
-0.957
-1.23
Basic Average Shares
4,259,540
2,718,433
1,680,308
1,625,805
Diluted Average Shares
4,259,540
2,718,433
1,680,308
1,625,805
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$2,254,173
(-0.35%↓ Y/Y)
Interest income
$53,055
(126.69%↑ Y/Y)
Operating loss
-$2,307,228
(-1.65%↓ Y/Y)
Total operating
expenses
$2,307,228
(1.65%↑ Y/Y)
General and
administrative
$1,235,692
(-29.21%↓ Y/Y)
Research and development
$1,071,536
(104.41%↑ Y/Y)
Buy us a coffee
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)